High function and quality controlled iPS-derived cardiomyocytes available to the global drug discovery market.
Contact us to learn more about the services and products we supply.
1. SARCOMERE STRUCTURES
CarmyA are produced in 3D and chemically-defined culturing conditions, which induces further maturation as cardiac cells with having better sarcomere structures showing more patterned Z-bands compared with conventional 2D culturing methods.
2. KEY MARKER EXPRESSIONS
CarmyA expresses higher voltage-dependent K+ channel genes (HERG, KCNQ1, Kir1.2) than other commercially available iPS-derived cardiomyocytes. CarmyA also shows matured electrophysiological properties.
3. DRUG RESPONSES
CarmyA shows good arrhythmia responses (long QT, EAD and bradycardia) with introducing Terfenadine and Verapamil.
CarmyA shows clear intracellular Ca2+ wave prolongation (long QT) and EAD (Early After Depolarization) with dosing E4031, a typical HERG channel blocker.
3.2. ISOPROTERENOL, TERFENADINE
CarmyA shows more typical cardiotonic responses (compared with conventional iPS-derived cardiomyocytes) with showing tachycardia with being exposed to Isoproterenol – a typical cardiotonic drug. CarmyA also shows clearer Ca2+ wave prolongation with being exposed to Terfenadine – a typical long QT compounds.
4. MITOCHONDRIA ACTIVITY
CarmyA shows stronger mitochondrial activities compared with conventional iPS-derived cardiomyocytes.
5. ORIGINAL SOFTWARE FOR FLUORESCENCE AND MOTION ANALYSIS
Myoridge co-developed our original software being able to visualize both fluorescence and motion peaks. This software also provides good Ca2+ visualization in multi-well plates, therefore suitable good for high throughput analysis.
6. ESTABLISHED QUALITY CONTROL AND LOGISTICS MANAGEMENT
Myoridge established its own quality control systems with guaranteeing the cell numbers and key functions as cardiomyocytes. Customers are able to access our quality data sheet (certificates of analysis) upon request before placing orders. CarmyA are cryopreserved and delivered to world-wide using special cryogenic delivery services.
Myoridge is a Kyoto University spin-out company having licenses of commercialization of iPS-derived cardiomyocytes under chemically-defined and protein-free conditions on 3D platform. The CarmyA production platform provides highly purified and functional cardiomyocytes guaranteeing narrower lot-to-lot variation.
3D Culturing Conditions
90 to 98 % purity (as cTnT + CMs)
Excellent Drug Responding Properties